Breffi (Brefi)

Breffi is an industry company omnikanalny marketing for pharmaceutical the sector in. Russia The company promotes pharmaceutical brands mainly through the medical community, using comprehensive remote and digital channels.

History

2021: Acquisition of share by Elbrus Capital Fund III for RUB 750 mln.

The fund Elbrus Capital Fund III acquired a large minority stake in Breffi, the Russian omnikanalny marketing pharmaceutical a brand company. This Elbrus Capital was announced Zdrav.Expert on December 29, 2021. The transaction amount amounted to 750 million rubles. Most of the funds will be used to develop the company, scale the current business and create new digital products in the field. health care

The Russian service for the promotion of medicines Breffi immigrants from AstraZeneca attracted 750 million rubles
Source photo: forma-group.ru

Breffi was founded in 2012 by immigrants from AstraZeneca - Yevgeny Gordeev and Irina Shramova. Since its foundation, the main focus of the company has been the promotion of branded drugs in Russia, mainly through the medical community. As of December 2021, Breffi has more than 100 customers, most of whom are international pharmaceutical companies with a presence in Russia. Breffi's revenue in 2021 amounted to more than 500 million rubles.

The key driver of Breffi's development is the promotion of pharmaceutical brands through remote and digital channels. The company actively uses approaches based on dynamic data analysis, automation of communication processes with the target audience and the use of its own IT platforms. Breffi is a reformer offering the pharmaceutical market new, digital methods of promotion. A distinctive feature of the Breffi offer for its customers, among others, is the guarantee of their return on investment in brand promotion.

For Breffi, this is the first experience in attracting third-party equity. Investments received from the Elbrus Capital Fund will be aimed at further business development. The company plans to scale operating services, reach promising related areas and strengthen the development of IT products. The parties do not disclose the company's assessment. The founders of the company, Yevgeny Gordeev, Irina Shramova and Anton Bondarenko, will continue to manage the business, maintaining control in decision-making.

This investment for Breffi is primarily an opportunity to be more competitive in the fight for market experts. We will be able to realize what we have long dreamed of - significantly strengthen the development of our employees, have more opportunities for high-quality implementation of projects, for experiments and creativity. Partnership with the Elbrus Capital Foundation is the first phase of our five-year development strategy, as a result of which we will help millions of patients to have a higher quality of life. said Evgeny Gordeev.

Breffi services become especially relevant as the pharmaceutical industry continues to digitalize and contacts with doctors shift from traditional meetings with medical representatives to digital channels. We hope that with the support of the Elbrus Capital Fund, the company will be able to further strengthen its position in the omnichannel marketing market in the pharmaceutical sector, accelerate development and multiply grow on the horizon of several years, commented by Alexander Savin, Senior Partner of Elbrus Capital Funds.

2019

As of August 2019, the main activity of the company was consulting on commercial activities and management.